Although this hypothesis needs to be further elucidated, data from clinical studies indicate that DPP4 participates in the coronavirus disease 2019 (COVID-19) physiopathology and therefore is a therapeutic target for this disease. The gene discussed is DPP4; the disease is COVID-19.